BDX as reported
Becton Dickinson reported $23.3B of revenue over the trailing twelve months, +17% on the year before. 11 reported series are charted on this page, each one as filed.
$23.3B
Revenue, trailing twelve months · to Q3 2026 · +17% against the twelve months before
- Net Income
- $941M
Net Income · −41% year on year · trailing twelve months to Q3 2026
- Op Margin
- 10.0%
Op Margin · trailing twelve months to Q3 2026
- EPS
- $3.32
EPS · −39% year on year · trailing twelve months to Q3 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $23.3B | +17% | Q3 2026 |
| Net Income | $941M | −41% | Q3 2026 |
| EPS | $3.32 | −39% | Q3 2026 |
| Gross Margin | 47% | n/a | Q3 2026 |
| Op Margin | 10.0% | n/a | Q3 2026 |
| Net Margin | 3.5% | n/a | Q3 2026 |
| ROE | 5.5% | n/a | Q3 2026 |
| ROA | 2.6% | n/a | Q3 2026 |
| ROIC | 5.0% | n/a | Q3 2026 |
| Free Cash Flow | $2.97B | n/a | Q1 2025 · 6 quarters behind |
| P/E | 57.3 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Becton Dickinson (BDX) - Revenue & ProfitRevenue & ProfitBecton Dickinson (BDX)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Medical Instruments & Supplies
Ranks #17 of 27 by Smart Score